Combo immunotherapy ups survival in advanced liver cancer

(HealthDay)—STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as first-line therapy for unresectable hepatocellular carcinoma (uHCC), according to a study presented at the annual American Society of Clinical ...

Oncology & Cancer

Interferon not beneficial for most stage III melanoma

Final results for the Sunbelt Melanoma Trial, published online this month in the Journal of Clinical Oncology, show that thanks to current diagnostic techniques, most stage III melanoma patients do not benefit from treatment ...

Oncology & Cancer

Drug shows promise for subset of stage III colon cancer patients

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological ...

page 1 from 4